Deutchman Mark, Wulster-Radcliffe Meghan
Department of Family Medicine, University of Colorado Health Sciences Center at Fitzsimons, Aurora, USA.
MedGenMed. 2005 Dec 6;7(4):62.
Stress urinary incontinence (SUI) is the most common form of urinary incontinence in women and is associated with high financial, social, and emotional costs. The history and physical examination can identify most patients with a significant stress incontinence component without the need for urodynamic testing. A variety of pharmacologic agents have been used off-label, but an evidence-based pharmacologic treatment has not been readily available. The development of a selective serotonin and norepinephrine reuptake inhibitor will add a potentially useful drug to the primary care physician's practice for treating female patients with SUI. In August 2004, a selective serotonin and norepinephrine reuptake inhibitor, duloxetine, became the first medication approved for the treatment of women with moderate to severe SUI throughout the European Union. As of November 2005, however, duloxetine has not been approved for the treatment of SUI in the United States.
压力性尿失禁（SUI）是女性中最常见的尿失禁形式，且会带来高昂的经济、社会和情感成本。病史和体格检查能够识别出大多数有明显压力性尿失禁成分的患者，而无需进行尿动力学检测。多种药物已被超适应证使用，但尚未有基于证据的药物治疗方法。一种选择性5-羟色胺和去甲肾上腺素再摄取抑制剂的研发，将为初级保健医生治疗患有SUI的女性患者增添一种潜在有用的药物。2004年8月，一种选择性5-羟色胺和去甲肾上腺素再摄取抑制剂——度洛西汀，成为整个欧盟首个被批准用于治疗中重度SUI女性的药物。然而，截至2005年11月，度洛西汀在美国尚未被批准用于治疗SUI。
